Semax vs Humanin
Both Semax and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
Semax
Evidence BSemax (MEHFPGP)
A synthetic ACTH fragment that increases BDNF levels and enhances focus, memory, and mental clarity. Delivered intranasally for rapid cognitive effects.
View full Semax profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | Semax | Humanin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved in US — approved in Russia for stroke and cognitive disorders | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 200–600 mcg intranasal, morning | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 89 | 5 |
| Categories | cognitive, neuroprotection | mitochondrial, longevity, neuroprotection |
Key reported benefits — Semax
- ✓BDNF increase
- ✓Enhanced focus
- ✓Memory improvement
- ✓Neuroprotection
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.